Administration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. However, several cases of pregnant women being treated with rituximab are reported herein; an exception is often made in cases with grave illness. We describe an exceptional case of a woman with non-Hodgkin lymphoma of the mucosa-associated lymphoid tissue type where rituximab was given as a single agent without interruption during two consecutive pregnancies. This case can certainly supply important indications on the safety of rituximab.

Use of rituximab in NHL malt type pregnant in I° trimester for two times / Sica, A.; Vitiello, P.; Papa, A.; Calogero, A.; Sagnelli, C.; Casale, D.; Mottola, M.; Svanera, G.; Dodaro, C. A.; Martinelli, E.; Troiani, T.; Ciardiello, F.; Casale, B.. - In: OPEN MEDICINE. - ISSN 2391-5463. - 14:1(2019), pp. 757-760. [10.1515/med-2019-0087]

Use of rituximab in NHL malt type pregnant in I° trimester for two times

Vitiello P.;Papa A.;Calogero A.;Dodaro C. A.;Ciardiello F.;Casale B.
2019

Abstract

Administration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. However, several cases of pregnant women being treated with rituximab are reported herein; an exception is often made in cases with grave illness. We describe an exceptional case of a woman with non-Hodgkin lymphoma of the mucosa-associated lymphoid tissue type where rituximab was given as a single agent without interruption during two consecutive pregnancies. This case can certainly supply important indications on the safety of rituximab.
2019
Use of rituximab in NHL malt type pregnant in I° trimester for two times / Sica, A.; Vitiello, P.; Papa, A.; Calogero, A.; Sagnelli, C.; Casale, D.; Mottola, M.; Svanera, G.; Dodaro, C. A.; Martinelli, E.; Troiani, T.; Ciardiello, F.; Casale, B.. - In: OPEN MEDICINE. - ISSN 2391-5463. - 14:1(2019), pp. 757-760. [10.1515/med-2019-0087]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/794912
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
social impact